Senators Rick Scott of Florida and Kirsten Gillibrand of New York introduced a bipartisan proposal that would finally require prescription drug bottles to list exactly where the medicine and its active ingredients were manufactured.
The “Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings” Act—better known as the CLEAR LABELS Act—targets a massive gap in current federal law.
While most consumer products like clothes or electronics must disclose their country of origin, prescription drugs sold in the U.S. often do not. This leaves patients and doctors unaware that many medications, particularly generics, are sourced from China and India.
The bill follows a joint investigation by the Senate Special Committee on Aging, which highlighted a heavy reliance on foreign-made pharmaceuticals in the United States. Supporters of the act argue that the lack of transparency makes it difficult for the public to vet the safety and oversight standards of facilities that produce their pills.
READ: Pennsylvania And New Mexico Senate Dems Help Advance Markwayne Mullin For DHS Secretary
“As parents and grandparents, we do everything we can to make informed, safe decisions that keep our families safe and healthy,” Florida Senator Rick Scott said during the announcement. “But right now, families are being kept in the dark about where their drugs are coming from.”
If passed, the legislation would mandate that labels disclose the original manufacturers for both the finished drug and the Active Pharmaceutical Ingredients (APIs) inside. Proponents say this will help pharmacists and healthcare providers make better-informed purchasing decisions while encouraging a shift back toward domestic manufacturing.
New York Senator Kirsten Gillibrand emphasized that the goal is simply to give consumers the same rights they have in other industries.
“Americans deserve to know where their prescription drugs are manufactured so they can make informed health care decisions,” Gillibrand stated. “The CLEAR LABELS Act would shine a light on pharmaceutical manufacturing by making this information readily accessible.”
The bill has gained additional support from Senators Ron Johnson, Tommy Tuberville, and Katie Britt. Senator Tuberville noted that Americans have become “way too reliant on foreign supply chains,” calling the move for clear labeling “common sense.”
The proposal now moves to the committee level for further review. If it becomes law, it would represent one of the most significant changes to pharmaceutical labeling in decades, effectively ending the era of “blind” prescriptions for millions of American households.
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox
